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Low socioeconomic position (SEP) is associated with an increased risk of cardiovascular disease (CVD), and 
social inequities exist also in the treatment of CVD and asso-
ciated outcomes.1–4 According to a recent American Heart 
Association policy statement, the greatest opportunity for 
reducing death and disability from CVD lies in dealing with 
their social determinants (including SEP).5
Statins reduce all-cause mortality and major vascular 
events in the primary prevention of CVD.6 However, many 
patients who are prescribed statins, especially those in pri-
mary prevention, do not adhere to the treatment.7 Low SEP is 
one of the predictors of nonadherence to preventive therapies, 
including statins, although previous research has reported 
varying results on the strength of this association.7,8 Several 
studies,7,9–12 yet not all,13 have found low income to predict 
statin nonadherence. Results on the association between edu-
cation and statin nonadherence are mixed: low education level 
has been associated with statin nonadherence,9,10 but higher 
education has also been found to predict statin nonadher-
ence9,11,13 or there has been no association.14
Research on the association between SEP and statin 
adherence has mainly defined adherence through measures 
that reduce longitudinal medication-taking behavior into 
a single number,12,13 such as the proportion of days covered 
(PDC).7,9 Although this simplification is appealing, it leads to 
loss of information on medication-taking patterns over time. 
Group-based trajectory modeling (GBTM)15 offers an alterna-
tive method for summarizing longitudinal data on medication 
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adherence. GBTM accounts for the dynamic nature of adher-
ence and identifies long-term patterns of the repeatedly 
measured adherence and groups of individuals with simi-
lar patterns.16,17 Statin adherence trajectories have also been 
shown to predict cardiovascular events.18
Despite the universal healthcare, socioeconomic dispari-
ties in CVD have been documented also in Finland: lower 
SEP has been associated with higher CVD morbidity and 
mortality, lower use of statins, and lower revascularization 
rates.3,19–21 The aim of our study was to determine the associa-
tion of SEP with nonadherence and adherence trajectories in 
Finnish patients initiating statin therapy for primary preven-
tion of CVD. To refine the estimation of the effect of SEP 
on statin nonadherence, we measured adherence as 18-month 
adherence trajectories in addition to a conventional dichoto-
mous measure (PDC <80% versus ≥80%). These associations 
were analyzed separately among men and women because 
there are reports of sex differences in associations between 
SEP and statin use.4,9,21 We focused on primary prevention 
where the associations between SEP and statin adherence are 
poorly known because published studies have been mainly 
among secondary prevention or mixed cohorts including both 
primary and secondary prevention patients.7,10–14
Methods
Data Sources
Our study was based on data extracted from administrative healthcare 
databases, and registers maintained by Statistics Finland. Statistics 
Finland provided information on marital status and SEP and linked 
the data from different registers through unique personal identifica-
tion numbers. We had access to deidentified data only.
The Prescription Register, maintained by the Social Insurance 
Institution of Finland since 1994, is a pharmacy claims database 
that includes records of all medication dispensations reimbursed to 
noninstitutionalized residents of Finland.22 For each dispensation, 
the register contains data on the medication (eg, the Anatomical 
Therapeutic Chemical classification code,23 dispensation and pre-
scription dates, dispensed quantity, cost, and copayment) and on 
the patient (eg, sex, birth, and death dates). During long-term 
institutionalizations (>90 consecutive days) and hospital stays, pa-
tients are not eligible for drug reimbursement, and their medica-
tion use is not recorded in the Prescription Register. The Social 
Insurance Institution of Finland maintains also the Special Refund 
Entitlement Register that includes records of patients entitled to a 
higher medication reimbursement  because of certain severe chron-
ic diseases, such as diabetes mellitus, hypertension, and coronary 
heart disease (CHD).
The hospital discharge register is maintained by the National 
Institute for Health and Welfare.24 Covering all Finnish hospitals, it 
includes data on discharge diagnoses (the International Classification 
of Diseases, Tenth Revision codes since 1996), procedure codes, and 
admission and discharge dates.
Cohort
All noninstitutionalized, 45- to 75-year-old residents of Finland ini-
tiating statin therapy between January 1, 2001, and December 31, 
2004, were identified. A new statin user was defined as a patient with 
no previous statin dispensations in the Prescription Register since 
1994. To enhance patient confidentiality, an 85% random sample of 
these initiators was included in our study. The date of the first statin 
dispensation was used as the index date (ie, the date of cohort entry).
For reliable identification of covariates, individuals institutional-
ized for long-term during 3 years before statin initiation were exclud-
ed. We also excluded patients who were dispensed lipid-modifying 
drugs other than statins within 3 years preceding the cohort entry and 
those initiating treatment with cerivastatin (withdrawn from the mar-
ket in 2001).
We focused on primary prevention of atherosclerotic CVD. 
Therefore, we excluded patients in secondary prevention defined as 
hospitalization for CHD (International Classification of Diseases, 
Tenth Revision codes I20–I25), cerebrovascular diseases (I60–I66, 
I68, I69, G45, and G46), atherosclerosis (I70), aneurysm (I71), or 
any medical procedure related to CHD, cerebrovascular diseases, 
or peripheral artery disease within 3 years before the index date. 
Dispensations of nitrates during 3 years preceding and the entitlement 
to special refund because of CHD at statin initiation were also used for 
defining secondary prevention. We excluded patients aged <45 year as 
their proportion of statin initiators was low and those aged >75 years 
because the benefits of statin therapy in this age group are unclear.25
Patients were followed-up for 18 months since the index date. We 
excluded patients who died or were institutionalized for long-term 
during the follow-up or were hospitalized for 30 days in any of the 
follow-up months. 
Details of the exclusion criteria are presented in Table I in the 
Data Supplement.
No ethics committee approval was required because we used only 
deidentified patient data and did not contact any patients. The Social 
Insurance Institution of Finland, the National Institute for Health and 
Welfare, and Statistics Finland granted us permission to use their reg-
ister data.
Adherence
We identified statin dispensations during 540 days since the index 
date. Based on these dispensations, we defined for each patient 
whether statin was available on each day during the follow-up. 
Because the Prescription Register has no data on dosages or days’ 
supply, we assumed a dosage of 1 statin tablet per day.26 If there was 
overlapping refills, we assumed that the patient finished the previous 
supply before the use of the new supply. Switching between statins 
was not considered as treatment discontinuation.
The PDC27 for the whole 540-day follow-up was obtained by di-
viding the number of days covered by the number of nonhospitalized 
days during the follow-up. For GBTM, we calculated the PDC for 
every 30-day period (18 in total) by dividing the number of days cov-
ered by the number of nonhospitalized days during each period to cre-
ate monthly binary indicators for adherence and to obtain adherence 
patterns for each patient. Nonadherence was defined as PDC <80%28 
for the whole follow-up and the monthly indicators.
WHAT IS KNOWN
•	 Negative effects of low SEP on adherence to statins 
have been previously reported; however, less is 
known about these associations in primary preven-
tion populations and their variation by sex.
WHAT THE STUDY ADDS
•	 Low SEP is associated with statin nonadherence, 
especially rapid decline in adherence, among men.
•	 Among women, the relationship between SEP and 
statin nonadherence is not obvious.
•	 These associations were documented in a primary 
prevention population in a country with universal 
healthcare and drug reimbursement systems, using 
three indicators of SEP and two adherence measures: 
the proportion of days covered and adherence trajec-
tories modeled by group-based trajectory modeling.
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Socioeconomic Position
We used 3 SEP indicators: income, education level, and labor market 
status (Table II in the Data Supplement). All of these variables were 
measured in the year of statin initiation. If data were missing in that 
year, the previous year’s data were used. Personal taxable income 
was divided into quintiles in the whole cohort (ie, not sex-specific). 
Education level refers to the highest completed education/degree 
and had 3 categories: basic, secondary (high school and vocational 
qualifications), and higher-degree level (university or college educa-
tion). Labor market status was categorized as employed, unemployed, 
retired, and outside the labor market (eg, students, caregivers, and 
homemakers).
Covariates
We obtained information on sociodemographic factors, cardiac and 
noncardiac comorbidities, and copayments. These covariates were 
selected based on their potential connection with statin adherence or 
cardiovascular risk.7,29 A comprehensive list of covariate definitions is 
presented in Table II in the Data Supplement.
We included the following sociodemographic variables: age, sex, 
marital status, and residential area measured on the index year. If 
there were missing data about marital status, we used data from the 
previous year. Residential area refers to the 5 tertiary care catchment 
areas in Finland.
Most of the comorbidities were identified using discharge diag-
noses (3 years preceding the index date), reimbursed medications 
(dispensed ≤1 year before or on the index date), and entitlements to 
special refund (valid at the index date).24 We identified the number of 
hospital days in the year preceding the index date, and the number of 
different medications dispensed and total medication costs shared by 
the patient during the 120 days preceding statin initiation (including 
the index date). We did not have data on patients’ cholesterol or blood 
pressure levels or smoking to directly determine their CVD risk.
We also included variables related to statin initiation: time of 
initiation (quarter/yr), type, and intensity of the initial statin therapy 
(modified from Stone et al25), and copayment of the first statin dispen-
sation (per tablet). Time of statin initiation was included as a design 
variable to adjust for secular trends in statin prices (generic substitu-
tion introduced in Finland in April 2003), prescribing practices, and 
possible changes in the coverage of the Prescription Register. 
Age, number of hospital days, and copayment of the first statin 
were categorized to allow for nonlinear associations with adherence.
Statistical Analyses
Group-Based Trajectory Models
We modeled the monthly binary indicators as a longitudinal response 
in a logistic GBTM to classify patients by their statin adherence.15,17 
GBTMs are an application of finite mixture models and they use the 
maximum likelihood method to estimate model parameters.15 These 
parameters determine, for example, the shape of the trajectories and 
the estimated trajectory group sizes. The models also produce poste-
rior probabilities of group membership that measure each individual’s 
likelihood of belonging to each of the trajectory groups given the in-
dividual’s adherence pattern. According to the maximum posterior 
probability assignment rule, individuals are placed into the trajectory 
group with the highest posterior probability.
We tested models for the whole cohort using 2 to 6 groups. As 
documented in the previous work, models with 6 groups were as-
sumed to be too difficult to interpret.17 The selection of the final mod-
el was based on the Bayesian information criteria (value closest to 0 
indicating the best-fitting model).15 Modeling was performed using 
Proc Traj.30 SAS version 9.3 (SAS Institute Inc., Cary, NC) was used 
for all statistical analyses.
Binary and Multinomial Logistic Regressions
We explored the associations between SEP and adherence with 4 
different models: models including only one of the SEP indicators 
(income, education, or labor market status model), and a full model 
including all SEP indicators to see how the indicators influence each 
other’s associations with nonadherence. The association between 
patients’ SEP and nonadherence was explored with binary logistic 
regression with nonadherence as the outcome (PDC <80% measured 
over the 540 days). The associations between SEP and membership 
in statin trajectory groups were estimated with multinomial logistic 
regression models. We observed significant interactions between sex 
and each SEP indicator (P<0.001 for interaction terms sex×income 
quintile, sex×education level, and sex×labor market status in separate 
SEP models based on the whole cohort), which supported our deci-
sion to stratify the data by sex.
In total, 576 individuals (0.5%) in our final cohort had missing 
data (480 on income, 50 on labor market status, 50 on marital sta-
tus, and 154 on residential area). These individuals were included in 
GBTM but not in the logistic regressions. Because of the low rate of 
missingness, we did not impute missing data.
Results
Cohort
Our original sample included 174 496 new statin users. The 
final cohort included 116 846 primary prevention patients with 
full adherence data (51 590 men and 65 256 women; flow-
chart of the cohort definition in Figure I in the Data Supple-
ment). The baseline characteristics and adherence measures 
are displayed in Table 1. Men’s mean age was 58.0 years, 
and women’s mean age was 60.8 years. Men had distinctly 
higher income than women (men’s mean yearly income 
€30 700 versus women’s €18 200). Most of men (40.7%) and 
women (49.2%) had only basic education. Of men, 52.0% 
were employed and 36.2% were retired. Conversely, 37.2% 
of women were employed and 49.0% were retired. Baseline 
characteristics according to adherence trajectories are dis-
played in Tables III and IV in the Data Supplement.
Associations of SEP With Dichotomous 
Nonadherence
During the 18-month follow-up, 50.5% of the whole cohort 
were nonadherent (PDC <80%; 51.3% of men and 49.9% 
of women). In men, nonadherence was dependent on SEP. 
The association with income was monotonic: the lower the 
income, the higher the odds of nonadherence (test for trend: 
P<0.001; Table 2). Men with basic or secondary education 
were 1.18× as likely (95% confidence intervals, 1.13–1.24) 
as men with higher-degree education to be nonadherent; the 
corresponding odds ratios (ORs) were 1.17 (95% confidence 
interval, 1.10–1.25) for those unemployed and 1.35 (95% con-
fidence interval, 1.18–1.55) for those outside the labor market 
compared with employed men. Among women, no clear asso-
ciation between income or education and nonadherence was 
observed (Table 3). The OR of nonadherence was 1.11 (95% 
confidence interval, 1.00–1.55) for women outside the labor 
market compared with employed women.
Adherence Trajectories
Based on Bayesian information criteria values and model 
convergence, we selected the 6-group cubic model as the 
final GBTM (Table V in the Data Supplement). According to 
diagnostic criteria, the selected model performed adequately 
(Table VI in the Data Supplement). The estimated 6 trajec-
tories and the averaged group data are presented in Figure 1. 
The following 6 adherence patterns were identified: (1) very 
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  Charlson comorbidity index 0.2±0.5 0.2±0.5 0.2±0.5
  No. of hospital days 2.1±7.9 2.1±7.0 2.1±7.4
  Use of NSAIDs 25.2 32.1 29.1
  Use of hormone therapy 0.0 35.8 20.0
  No. of concurrent 
medications
3.2±2.2 3.9±2.5 3.6±2.4
  Total out-of-pocket costs of 
medications, €
92.7±69.8 97.4±70.3 95.4±70.1
Statin factors
  Year of statin initiation*
   2001 21.3 21.6 21.4
   2002 22.5 22.7 22.6
   2003 24.7 24.5 24.6
   2004 31.5 31.2 31.3
  Statin at baseline
   Simvastatin 38.1 40.0 39.2
   Atorvastatin 37.3 34.8 35.9
   Rosuvastatin 10.5 9.7 10.0
   Fluvastatin 6.7 7.9 7.4
   Pravastatin 6.0 5.8 5.9
   Lovastatin 1.5 1.7 1.7
  Intensity of statin therapy†
   Low 26.7 32.2 29.8
   Moderate 72.7 67.4 69.7
   High 0.6 0.3 0.4
  Copayment of first statin 
dispensation, euro cents/
tablet
68.8±25.9 67.2±25.7 67.9±25.8
Adherence
  PDC during 1.5 y 67.8±31.3 69.0±30.9 68.5±31.1
  PDC <80% during 1.5 y 51.3 49.9 50.5
  Assignment to trajectories
   Very rapidly declining 
adherence
16.6 15.5 16.0
   Rapidly declining 
adherence
6.4 6.3 6.3
   Varying adherence 17.4 17.0 17.2
   Slowly declining 
adherence
9.1 9.6 9.4
   Mild nonadherence 29.3 27.9 28.6
   Near-perfect adherence 21.2 23.6 22.5
Data are expressed as mean±SD or percentage. 
COPD indicates chronic obstructive pulmonary disease; CV, cardiovascular; 
and PDC, proportion of days covered.
*Time of statin initiation was used as quarter/y in the logistic regressions.
†Low intensity: F10–40, L10–20, P10–20, S5–10; moderate intensity: A10–
20, F80, S20–40, L40, P40–80, R10; and high intensity: A40–80, R20–40, S80.
Table 1. Continued
 
Men 
(n=51 590)
Women 
(n=65 256)
All 
(n=116 846)
Table 1. Baseline Characteristics and Adherence of Statin 
Initiators
 
Men 
(n=51 590)
Women 
(n=65 256)
All 
(n=116 846)
Socioeconomic and demographic factors
  Taxable income, €/y 30 698± 
27 662
18 154± 
13 664
23 699± 
21 937
  Education level
   Basic 40.7 49.2 45.4
   Secondary 30.5 30.6 30.6
   Higher-degree 28.8 20.2 24.0
  Labor market status
   Employed 52.0 37.2 43.7
   Unemployed 9.9 11.1 10.6
   Retired 36.2 49.0 43.4
   Outside the labor market 1.9 2.8 2.4
  Age, y 58.0±7.7 60.8±7.8 59.6±7.9
  Marital status
   Unmarried 8.3 7.4 7.8
   Married 81.9 68.8 74.6
   Divorced 7.9 11.9 10.2
   Widowed 1.8 11.8 7.4
  Geographical region of Finland
   Southern 31.2 31.2 31.2
   Southwestern 13.6 13.4 13.5
   Central 22.5 23.1 22.8
   Eastern 18.9 19.3 19.1
   Northern 13.8 13.0 13.4
Cardiac comorbidities
  Dyslipidemia 1.2 0.9 1.1
  Diabetes mellitus 17.2 11.8 14.2
  Hypertension 51.2 53.2 52.3
  Cardiac insufficiency 1.5 1.0 1.2
  Atrial fibrillation 4.1 2.0 2.9
  No. of concurrent CV 
medications
0.9±1.1 0.9±1.0 0.9±1.0
Noncardiac comorbidities and copayments
  Dementia 0.3 0.4 0.4
  Depression 7.0 11.5 9.5
  Mental disorder 2.7 3.7 3.2
  COPD and asthma 8.0 11.6 10.0
  Cancer 3.1 4.3 3.7
  Rheumatoid arthritis 1.8 3.1 2.5
  Renal insufficiency 0.3 0.2 0.2
  Obesity 0.6 0.6 0.6
  Alcoholism/narcomania 1.0 0.4 0.7
(Continued )
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rapidly declining adherence including individuals with virtu-
ally no dispensations after initiation (estimated size 16.0% of 
the whole cohort), (2) rapidly declining adherence represent-
ing rapid decline in statin use (6.3%), (3) varying adherence 
representing fluctuating use across the follow-up (17.2%), (4) 
slowly declining adherence representing a steady decline in 
statin use (9.4%), (5) mild nonadherence including individu-
als improving statin use after a slight decrease (28.6%), and 
(6) near-perfect adherence including individuals being nearly 
always adherent (22.5%).
Associations of SEP With Adherence Trajectories
Figure 2A through 2F shows which adherence trajectories 
men and women were assigned to according to the 3 SEP 
indicators. Near-perfect adherence trajectory was over-repre-
sented in men in the highest income quintile and with higher-
degree education and in women in the lowest income quintile 
and with basic level education. A higher proportion of retired 
patients was assigned to the highest adherence trajectory 
compared with the other labor market status categories in 
both sexes.
We used the trajectory of near-perfect adherence as the 
reference in the multinomial logistic regressions. Results 
from these analyses were mostly in line with the results based 
on dichotomous nonadherence. Among men, lower income 
and education were associated with higher odds (ORs, 1.12–
1.62) of belonging to the 4 poorest adherence trajectories 
(Table 2). Unemployed men and men outside the labor mar-
ket had higher odds (ORs, 1.16–1.60) of belonging to the 3 
poorest adherence trajectories compared with employed men; 
retired men did not differ from the employed. The odds of 
belonging to the trajectories of rapidly declining adherence 
were higher than the odds of belonging to the 3 other trajec-
tories regardless of the SEP indicator used (except for unem-
ployed men).
Among women, there were few significant associations 
between income and adherence trajectories, which supports 
the results based on dichotomized PDC (Table 3). Basic edu-
cation was associated with smaller odds (ORs, 0.87–0.91) of 
belonging to the trajectories of varying or slowly declining 
adherence or mild nonadherence. Retired women had smaller 
odds (ORs, 0.77–0.85) of belonging to any of the nonadher-
ence trajectories. In contrast to associations with dichotomized 
PDC, unemployed women had smaller odds (ORs, 0.83–0.88) 
of belonging to any of the nonadherence trajectories except 
rapidly declining adherence. Furthermore, women outside the 
labor market had smaller odds (ORs, 0.75–0.83) of belonging 
to the trajectories of varying or slowly declining adherence or 
mild nonadherence.
The results about the sex difference in the relationship 
between income and statin adherence did not depend on the 
use of nonsex-specific quintiles, because in sensitivity analy-
ses using sex-specific quintiles, the sex differences remained 
(Table VII in the Data Supplement).
Full Models
When mutually adjusted for other SEP indicators, the SEP–
nonadherence associations attenuated among men in both 
binary and multinomial logistic regressions (Table VIII in 
the Data Supplement). In women’s full models, the asso-
ciations did not materially change (Table IX in the Data 
Supplement).
Table 2. Multivariable Odds Ratios* and 95% Confidence Intervals From Men’s Separate Socioeconomic Position Models for PDC 
<80% vs ≥80% and Nonadherence Trajectories vs Near-Perfect Adherence Associated With Income Level, Education Level, and 
Labor Market Status
Socioeconomic Position PDC <80%
Very Rapidly 
Declining Adherence
Rapidly Declining 
Adherence Varying Adherence
Slowly Declining 
Adherence
Mild 
Nonadherence
Income (n=51 374)
  First quintile (lowest) 1.41 (1.32–1.50) 1.62 (1.46–1.80) 1.48 (1.28–1.70) 1.29 (1.16–1.43) 1.23 (1.08–1.40) 0.98 (0.89–1.07)
  Second quintile 1.29 (1.21–1.37) 1.49 (1.35–1.64) 1.26 (1.10–1.44) 1.24 (1.12–1.36) 1.22 (1.08–1.37) 1.01 (0.93–1.10)
  Third quintile 1.22 (1.16–1.29) 1.31 (1.19–1.43) 1.25 (1.10–1.41) 1.22 (1.12–1.33) 1.20 (1.08–1.34) 1.01 (0.93–1.09)
  Fourth quintile 1.08 (1.03–1.14) 1.15 (1.06–1.25) 1.16 (1.04–1.30) 1.05 (0.97–1.14) 1.12 (1.02–1.23) 1.03 (0.96–1.10)
  Fifth quintile (highest) 1.0 1.0 1.0 1.0 1.0 1.0
Education (n=51 486)
  Basic 1.18 (1.13–1.24) 1.30 (1.21–1.40) 1.30 (1.18–1.44) 1.14 (1.06–1.23) 1.12 (1.02–1.22) 0.99 (0.93–1.05)
  Secondary 1.18 (1.13–1.23) 1.27 (1.18–1.37) 1.29 (1.16–1.43) 1.16 (1.08–1.25) 1.18 (1.08–1.29) 1.04 (0.97–1.11)
  Higher-degree 1.0 1.0 1.0 1.0 1.0 1.0
Labor market status (n=51 486)
  Unemployed 1.17 (1.10–1.25) 1.20 (1.08–1.33) 1.16 (1.01–1.34) 1.18 (1.07–1.31) 1.05 (0.93–1.19) 0.99 (0.90–1.09)
  Retired 0.99 (0.93–1.05) 0.97 (0.88–1.07) 0.97 (0.85–1.10) 0.94 (0.86–1.03) 0.92 (0.82–1.03) 0.93 (0.85–1.00)
  Outside the labor market 1.35 (1.18–1.55) 1.66 (1.34–2.05) 1.65 (1.26–2.17) 1.28 (1.02–1.60) 1.13 (0.86–1.48) 1.06 (0.87–1.30)
  Employed 1.0 1.0 1.0 1.0 1.0 1.0
PDC indicates proportion of days covered.
*All models were adjusted for the baseline characteristics (Table 1).
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Discussion
In this study of 116 846 statin initiators in Finland, low SEP 
was associated with statin nonadherence in men regardless 
of the indicator used. Lower income and education predicted 
overall nonadherence (PDC <80%) and specifically a rapid 
decline in adherence, as indicated by the trajectory model-
ing. In contrast, in women, income or education levels had no 
clear association with nonadherence. Also unemployment or 
being outside the labor market had stronger associations with 
nonadherence among men than among women. Conversely, 
being retired (versus employed) did not predict nonadher-
ence in men, but among women it predicted decreased odds 
of nonadherence.
The results on the relationship between SEP indicators and 
adherence trajectories were mostly in line with those obtained 
using dichotomous nonadherence (PDC <80%). However, tra-
jectory models allowed a more refined description of adher-
ence. The overall rates of statin nonadherence in this study 
were comparable to recent estimates from Finland31 and those 
from other countries.7 Also our trajectories were similar to 
those presented in previous research.17,18
Our results accord with a previous Finnish study of 
patients with CHD where socioeconomic disparities were 
found in statin use only among men.21 The previously reported 
association between lower income and lower statin adher-
ence7,9–12 was seen among men in our study. In line with our 
Table 3. Multivariable Odds Ratios* and 95% Confidence Intervals From Women’s Separate Socioeconomic Position Models for 
PDC <80% vs ≥80% and Nonadherence Trajectories vs Near-Perfect Adherence Associated With Income Level, Education Level, and 
Labor Market Status
Socioeconomic Position PDC <80%
Very Rapidly 
Declining Adherence
Rapidly Declining 
Adherence
Varying 
Adherence
Slowly Declining 
Adherence
Mild 
Nonadherence
Income (n=64 896)
  First quintile (lowest) 1.01 (0.95–1.08) 0.99 (0.89–1.10) 1.04 (0.90–1.19) 0.88 (0.80–0.98) 0.88 (0.78–0.99) 0.83 (0.76–0.90)
  Second quintile 0.99 (0.93–1.05) 0.99 (0.89–1.10) 1.04 (0.90–1.20) 0.89 (0.81–0.99) 0.89 (0.79–1.01) 0.86 (0.79–0.94)
  Third quintile 0.96 (0.90–1.02) 0.95 (0.86–1.06) 1.02 (0.89–1.17) 0.92 (0.83–1.01) 0.92 (0.82–1.04) 0.93 (0.85–1.01)
  Fourth quintile 1.00 (0.94–1.06) 0.99 (0.90–1.10) 1.06 (0.92–1.22) 0.99 (0.89–1.09) 1.00 (0.89–1.13) 0.99 (0.90–1.08)
  Fifth quintile (highest) 1.0 1.0 1.0 1.0 1.0 1.0
Education (n=65 205)
  Basic 0.95 (0.91–0.99) 0.96 (0.90–1.03) 0.91 (0.82–1.00) 0.89 (0.83–0.95) 0.87 (0.80–0.95) 0.91 (0.86–0.97)
  Secondary 0.98 (0.93–1.02) 1.02 (0.94–1.09) 0.97 (0.87–1.07) 0.96 (0.89–1.03) 0.99 (0.91–1.07) 1.00 (0.94–1.07)
  Higher-degree 1.0 1.0 1.0 1.0 1.0 1.0
Labor market status (n=65 205)
  Unemployed 0.96 (0.91–1.02) 0.88 (0.80–0.97) 0.89 (0.78–1.01) 0.85 (0.78–0.93) 0.88 (0.79–0.98) 0.83 (0.76–0.89)
  Retired 0.91 (0.86–0.96) 0.85 (0.78–0.93) 0.82 (0.73–0.92) 0.83 (0.76–0.91) 0.77 (0.69–0.85) 0.81 (0.75–0.87)
  Outside the labor market 1.11 (1.00–1.22) 0.99 (0.85–1.16) 1.16 (0.95–1.41) 0.83 (0.71–0.97) 0.79 (0.65–0.95) 0.75 (0.65–0.86)
  Employed 1.0 1.0 1.0 1.0 1.0 1.0
PDC indicates proportion of days covered.
*All models were adjusted for the baseline characteristics (Table 1).
Figure 1. Adherence trajectories. Solid 
lines present the predicted probability 
of being adherent (PDC ≥80%) in each 
group. Dashed lines present the observed 
proportion of adherent individuals in each 
group.
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results, in a Danish study,9 the income–adherence association 
was stronger among men, and income had virtually no impact 
on nonadherence in women aged 65 to 84 years.
Previous research has reported conflicting results on the 
association between education and statin adherence.9–11,13,14 
In a Danish study,10 higher education was associated with a 
lower risk of break in statin therapy among patients aged 30 
to 64 years but not among patients aged 65 to 74 years. Most 
of these studies were based on cohorts including both men 
and women.10,11,13,14 In the study by Wallach-Kildemoes et al,9 
Figure 2. Assignment to adherence trajectory groups by socioeconomic position indicator categories and sex: (A) men, income quintiles; 
(B) men, education level; (C) men, labor market status; (D) women, income quintiles; (E) women, education level; and (F) women: labor 
market status.
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higher education was associated with a lower risk of nonad-
herence among men but with a higher risk among women in 
whom the association was strengthened after adjustment for 
income. Our findings were similar to the preceding study 
although the slightly lowered risk of nonadherence among 
women with basic education (OR, 0.95) is not likely to be 
clinically significant. This finding highlights the need for 
future studies on the reasons for sex differences in effects of 
education on nonadherence. Potential reasons include engage-
ment in unhealthy lifestyle in general32 and lower health lit-
eracy among men with low education as lower health literacy 
has been linked with both male sex and low education.33 
Conversely, the controversy about the risks and benefits of 
statins may specifically affect the adherence of better educated 
women as they seem to have the greatest interest in health 
information.34
Low income and education were especially associated 
with rapidly declining adherence among men in our study. 
Cost-related barriers, even under universal healthcare and 
drug reimbursement, are a likely explanation for nonadher-
ence among men with low SEP in addition to the previously 
mentioned unhealthy lifestyle and lower health literacy. It 
seems that men with low SEP may need more support and 
more active follow-up especially at the beginning of treatment.
The reason for the absence of any clear association 
between SEP and statin adherence in women may be that 
there are other, stronger risk factors for women’s statin non-
adherence that mask the SEP differences. One of these factors 
may be adverse effects because, compared to men, women are 
more likely to report statin-related adverse effects and to stop 
statin treatment because of them.35
Strengths and Limitations
Strengths of our study include the usage of trajectory analysis 
to depict the development of nonadherence in addition to the 
overall dichotomized PDC. GBTM accounts for the dynamic 
nature of adherence and is, therefore, suitable for distinguish-
ing between different adherence behaviors because individuals 
with different behaviors may have identical PDC values.17 Our 
results suggest that trajectories could provide insight into statin 
adherence and its association with SEP indicators compared 
with the dichotomized PDC. However, as the results based on 
both adherence measures conveyed a similar message, the less 
sophisticated measurements may be sufficient, considering the 
workload related to conducting GBTM. For example, future 
studies could determine whether those with rapidly declining 
adherence can be identified with simpler indicators such as 
discontinuation after the first dispensation.36 Another strength 
of our study is that we used 3 different SEP indicators. SEP 
indicators are not interchangeable but partially independent 
and interindependent determinants of health.37 We also had 
access to individual-level SEP data instead of area-level data, 
and our cohort, whose reimbursement was not dependent on 
their income level, was relatively homogenous.
Our study has some potential limitations. First, we may 
have misclassified adherence. The Prescription Register 
includes only reimbursed medications and before 2006 medi-
cations were not reimbursed if a fixed deductible (€10 per 
dispensation) was not exceeded. Most importantly, we did not 
capture nonadherence resulting from dispensed but unused 
medications or from unfilled prescriptions (ie, primary non-
adherence). The true association between SEP and statin 
nonadherence may be stronger than the association shown in 
our study because our data included only patients who initi-
ated treatment. Finns with lower income or education have 
reported more often cost-related barriers to prescription medi-
cation use than individuals with higher income or education,38 
and higher income has been shown to be associated with bet-
ter primary adherence.39 Second, we may have misclassified 
patients’ labor market status in relation to statin initiation 
because this variable was based on data from the last week 
of the calendar year of initiation. Third, our data are from 
years 2001 to 2006. Although income differentials in Finland 
were nearly the same in 2012 as in 2001,40 the prices of statins 
have decreased potentially decreasing the differences across 
income groups. In the beginning of 2016, however, a €50 
annual deductible for medication reimbursements was intro-
duced in Finland,41 which may again widen differences in 
adherence across income groups. Furthermore, although clini-
cal guidelines nowadays recommend assessment of patients’ 
global CVD risk instead of CHD risk as the basis for treatment 
initiation, treatment goals are the same for the majority of pri-
mary prevention patients as during the study period (Table X 
in the Data Supplement).
Fourth, a model with >6 groups would have fitted the data 
better than our final model (Table V in the Data Supplement), 
suggesting that the distribution of person-specific trajectories 
is basically continuous. Although our decision on the number 
of trajectory groups was based on interpretability and previous 
research,17 the groups are more likely to be constructed than 
real. Fifth, our multivariable models included comorbidities 
that are plausibly mediators of the effect of SEP on adher-
ence.5 However, potential overadjustment would not affect our 
conclusions as the age-adjusted ORs between SEP indicators 
and adherence were close to the multivariable-adjusted ORs 
(Tables XI and XII in the Data Supplement). Finally, differ-
ences in the age distributions between employed and retired 
patients were considerable; thus, confounding by age may 
have masked the difference in nonadherence between retired 
and employed men and led to an apparent difference among 
women. A previous longitudinal study found that after retire-
ment, nonadherence increased among those who had started 
statin use while still employed.42
Conclusions
Lower SEP was associated with lower adherence among men, 
but these associations were weak and inconsistent among 
women according to both adherence measures. The use of 
GBTM provided insight into the dynamics of statin adher-
ence and its association with SEP indicators. Our results on 
the association between SEP and statin nonadherence call for 
more attention on patients with low SEP in Finland and other 
countries regardless of the health insurance and drug benefit 
systems.
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